Genentech Archives

Best in Biotech 20 Apr 2023

6 of the top biotech companies to know about in South San Francisco

South San Francisco is known as the birthplace of biotechnology, after Robert Swanson and Dr. Herbert Boyer founded biotech giant Genentech in 1976, eventually leading to other biotech companies and pharmaceutical companies basing themselves in the local area. In this article, we take a look at six biotech companies currently headquartered in South San Francisco. […]

April 20, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 20 Apr 2023

FDA approves Genentech’s lymphoma drug

Genentech, a member of the Roche Group, has announced the U.S. Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). The approval covers the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell […]

April 20, 2023 - 4 minutesmins - By Jim Cornall

In Depth 23 Dec 2020

Humble Beginnings: The Origin Story of Modern Biotechnology

The history of modern biotechnology began around four decades ago with the invention of genetic engineering. Genentech, one of the fundamental companies in this field, set many trends for modern biotech companies today. Biotechnology doesn’t necessarily involve labs. In fact, humans have been using forms of biotechnology for millennia, for example, using fermentation to brew […]

December 23, 2020 - 4 minutesmins - By Jonathan Smith

genentech immunocore immunotherapy pipette

News and Trends 20 Nov 2018

Genentech and Immunocore Expand Partnership to Develop Cancer Immunotherapy

Immunocore and the US biotech giant Genentech are building on their existing partnership to boost the clinical development of Immunocore’s immunotherapy for treating solid tumors. In the agreement, Genentech, a member of the Roche group, will pay UK-based Immunocore €87.3M ($100M) in an upfront payment and further undisclosed milestone payments as the immunotherapy progresses towards […]

November 20, 2018 - 2 minutesmins - By Jonathan Smith

Genome Sequence Human Genome Update Feature Header

In Depth 4 Sep 2018

The Past, Present and Future of Genome Sequencing

The last two decades have seen a revolution in genome sequencing with dramatic increases in speed and efficiency coupled with massive reductions in cost. There is so much going on in this area it can be difficult to keep up, so here is what you should know. Gene sequencing has proved its usefulness as a […]

September 4, 2018 - 9 minutesmins - By Editorial Team

antibiotic antibody staphylococcus symphogen 1

More News! 30 Nov 2017

Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib

A Phase Ib trial will assess the capacity of Symphogen’s antibody to direct an antibiotic to Staphylococcus infections for their effective treatment. Symphogen focuses on the development of antibodies for the treatment of cancer, but will receive a $5M (€4.2M) milestone payment from Genentech for the use of one of its antibodies against Staphylococcus aureus infections. It […]

November 30, 2017 - 2 minutesmins - By Alex Dale

News and Trends 17 May 2017

Way to Success: What Role does Company Culture Play in Biotech?

You’ve surely heard how great company culture is the key to the success of tech giants Google and Facebook. Does it also apply to biotech companies? Company culture is what drives employees to give their best every day for a cause they believe in. It’s what makes the best stay loyal to a firm over […]

May 17, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

AC Immune Genentech crenezumab phase III

News and Trends 28 Feb 2017

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

The Swiss biotech AC Immune announced that its partner Genentech (Roche) will start a second phase III clinical trial for its Alzheimer’s therapy crenezumab. In 2006 AC Immune partnered up with Genentech to bring its amyloid beta (Aβ)-targeting antibody crenezumab into the clinic. Although the compound did not meet its co-primary enpoints in the large phase II ABBY trial, Genentech pushed […]

February 28, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Dec 2016

Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments?

Hopes for an Alzheimer’s cure took a hit with Eli Lilly’s recent failure, but it’s not over yet. Probiodrug explains the failure and response. Alzheimer’s Disease devastates families and represents one of the largest financial burdens in society. Now the sixth leading cause of death for all age groups, the neurodegenerative disease cost the US […]

December 19, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 19 Oct 2016

The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved

Roche’s Genentech has received FDA approval for an immunotherapy targeting the highly sought-after PD-L1. The treatment may be able to outperform its competitors in lung cancer therapies. In May, Roche received approval for Tecentriq (atezolizumab) in bladder cancer. Now, the drug is expanding its indications to become the first and only cancer immunotherapy in the market to target […]

October 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Oct 2016

Big Pharmas Battle to be the Lung Cancer Leader at ESMO

Merck, Roche and BMS have unveiled updated results in Copenhagen as the companies duke it out for the leadership in lung cancer therapies. The conference of the European Society of Medical Oncology (ESMO) is underway in Copenhagen, and big pharma’s efforts to cure lung cancer are stealing the show. Three titans, Roche (Genentech), Merck and […]

October 10, 2016 - 3 minutesmins - By Evelyn Warner

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us